Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.77 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 5/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | ROS1 | P08922 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | BLK | P51451 | 1/20 | 0.46 |
| ▸ | BMX | P51813 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16206693 | 0.88 | EGFR (0.70) | EGFRSLC2A1LCKBTKBRD4 | |
| SCHEMBL16206734 | 0.88 | EGFR (0.61) | EGFRSLC2A1BRD4JAK3EML4 | |
| SCHEMBL15134743 | 0.88 | EGFR (0.79) | EGFRLCKBTKBRD4JAK3 | |
| SCHEMBL16195742 | 0.87 | EGFR (0.60) | EGFRSLC2A1EML4ALKFLT3 | |
| SCHEMBL16195432 | 0.87 | EGFR (1.00) | EGFRBTKJAK3JAK2BLK | |
| SCHEMBL16207287 | 0.86 | EGFR (0.59) | EGFRSLC2A1BRD4JAK3EML4 | |
| SCHEMBL16206740 | 0.85 | EGFR (0.58) | EGFRSLC2A1LCKBTKEML4 | |
| SCHEMBL15134722 | 0.85 | EGFR (0.60) | EGFRSLC2A1EML4ALKFLT3 | |
| SCHEMBL16206738 | 0.84 | EGFR (0.57) | EGFRSLC2A1LCKBTKEML4 | |
| SCHEMBL16195852 | 0.82 | EGFR (0.77) | EGFREML4ALKFLT3RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805940-B1 | PYRAZINE CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-9085540-B2 | Pyrazinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-07-21 | — | — | US | disclosed |
| US-9085540-B2 | Pyrazinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-07-21 | — | — | US | disclosed |
| EP-2805940-A1 | PYRAZINE CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | EGFR, ERBB2, ALK | EGFR 1/4885SLC2A1 4612/4885LCK 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.